• Rezolute highlighted two late-stage programs for ersodetug, an antibody targeting refractory hypoglycemia across hyperinsulinism forms via insulin receptor modulation.
• Phase 3 sunRIZE in congenital hyperinsulinism completed; primary SMBG endpoint missed due to functional unblinding, with CGM measures showing clinically meaningful hypoglycemia reductions.
• FDA reviewing analysis datasets and summary tables; program update expected in 2H 2026.
• Cash balance of USD 120 million; runway projected to mid-2028.
• Addressable US launch market estimated at about 1,500 pediatric congenital hyperinsulinism patients; management cited a USD 1 billion-plus global opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.